evergreening save recent report indicated sales atypical antipsychotics may enjoying apex long decision resources one world leading research advisory firms pharmaceutical healthcare issues finds generic competition end robust growth schizophrenia drug market atypical antipsychotic sales decrease billion billion five currently patent agents janssen risperdal risperdal consta risperidone eli lilly zyprexa olanzapine astrazeneca seroquel quetiapine pfizer geodon zeldox ziprasidone bristol myers squibb otsuka abilify aripiprazole lose patent protection united states risperidone first face generic competition united states europe japan generic competition effect risperdal brand profound market forecast patients generic form molecule price generic brand year said nitasha manchanda ph analyst decision resources risperdal consta depot form drug remains patent however use low preserve franchise sales approximately drug treated patients treated generic antipsychotic course hope manufacturers evergreening term many readers know loosely means extend patent life drug long possible antipsychotic drug manufacturers follow standard practices including following getting products approved new indications atypical antipsychotics rebranded broad spectrum psychotropic agents matters atypicals show substantial improvement efficacy safety existing products areas marketed increase marketing even generic competition arrives marketing blitz buy time release extended release format becoming time honored classic reformulate existing product molecule enough remarket brand new product work time seems case effexor sometimes works wonders celexa lexapro better yet prilosec nexium merck medco report food drug administration fda approvals last decade highlight prevalence evergreening strategies fda approved total new drug applications drugs containing existing active ingredients nearly half new formulations new fixed combinations existing drugs additional existing products marketed new manufacturer drag patent issues court long possible prevent release generic forms medication pay generic drug manufacturers create generic versions drug none likely actually yield substantial benefit patients one could argue extended release pills enhance compliance enhances outcomes i familiar data support assertion interesting brief article tactics go tool around pharmagossip site plentitude examples